https://www.selleckchem.com/pr....oducts/solcitinib.ht
PURPOSE Only a minority of patients with advanced non-small-cell lung cancer (NSCLC) truly benefit from single-agent PD-1 checkpoint blockade, and more robust predictive biomarkers are needed. EXPERIMENTAL DESIGN We assessed tumor samples from 67 immunotherapy-treated NSCLC cases represented in a tissue microarray, 53 of whom had pre-treatment samples and received monotherapy. Using GeoMx Digital Spatial Profiling system (NanoString), we quantified 39 immune parameters simultaneously in four tissue compartments defined by fluorescenc
Like
Comment
Share
